PainCast

Tag: glial cells

  • Targeting Glial Cells

    Targeting Glial Cells

  • MOA of SCS and Indications

    MOA of SCS and Indications

  • Molecular Biology of Pain

    Molecular Biology of Pain

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on November 24, 2020

    Dr. Nebojsa Nick Knezevic discusses innovative strategies to target the molecular mechanisms of pain. After reviewing nociceptive and neuropathic pain, inflammatory cytokines, and nociceptor diversity, he introduces pain-related voltage gated ion channels, glial and inflammatory cells, and G-protein-coupled receptor kinase 2 (GRK2). Dr. Knezevic provides compelling evidence that these are promising targets for pain treatment using strategies including monoclonal antibodies, biased μ-opioid receptor ligands, stem cells, and targeted gene therapy.

    [/vc_column_text][/vc_column][/vc_row]

  • Differential targeting in SCS- A feasibility study

    Differential targeting in SCS- A feasibility study

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on May 21, 2020

    Dr. Ramsin Benyamin discusses differential target multiplexed spinal cord stimulation (DTM-SCS) for chronic back pain. He starts with a comparison of neuronal and glial cell prevalence in the spinal cord before turning to the theory of targeted, multiplexed SCS and the value of glial targeting. Dr. Benyamin provides data from a prospective study demonstrating that DTM-SCS is significantly more effective in treating back and leg pain compared to standard SCS.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]